Cite
HARVARD Citation
Cebon, J. et al. (2020). Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. Journal for immunotherapy of cancer. 8 (1), p. . [Online].